KOSDAQBiotech & Pharma115480

CU Medical Systems

₩1,801▼ 6.20%2026-11-18 close
Market Cap
₩21.8B
Turnover
₩100M
Volume
60K
Shares out.
12.1M
PER
2.9×
PBR
0.3×
EPS
₩655
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

CU Medical Systems: Profit Recovery, Uneven Quarters

CU Medical Systems returned to attributable profit in 2025 and posted strong revenue and operating profit in the second quarter of 2026, but a small attributable net loss in the third quarter keeps quarterly volatility as the central issue.

  1. 1

    Annual revenue for 2025 was KRW 48.2 billion (up 18.7% year on year) and operating profit was KRW 10.8 billion (up 38.6%), giving an operating margin of 22.4%.

  2. 2

    Net profit attributable to controlling shareholders turned positive in 2025 at KRW 819 million, after net losses in 2023 and 2024.

  3. 3

    In the second quarter of 2026 revenue was KRW 20.2 billion and operating profit KRW 5.97 billion, the largest of the last five quarters; in the third quarter revenue fell to KRW 13.6 billion and attributable net loss was KRW 90.43 million.

  4. 4

    According to the company, about 80% of revenue comes from overseas, and it is showing the next-generation AED CU-SPX at MEDICA 2026, which opened on November 16, 2026.

  5. 5

    A 5-to-1 share consolidation that took effect on April 28, 2026, and early redemption of convertible bonds are steps that change the share count and capital structure.

02

Business structure

CU Medical Systems, founded in 2001 and listed on KOSDAQ in 2011, is a manufacturer specializing in automated external defibrillators (AEDs). According to the company's profile, its line-up covers consumer-grade AEDs, advanced defibrillators for medical professionals, training defibrillators and accessories.

Its next-generation model CU-SPX analyzes heart rhythm automatically to decide whether a shock is needed and guides the rescuer step by step through a 7-inch screen and voice prompts. The company exhibited the product at MEDICA 2026 in Düsseldorf, Germany, which runs until November 19, 2026.

The company says about 80% of revenue comes from overseas and that it currently exports to more than 80 countries. Because AED pads and batteries must be replaced periodically, the company notes that consumable sales tend to grow with the installed base.

Reports say a maternal and neonatal medical device subsidiary came under the group's control in January 2026, adding patient-monitoring and breast-pump products. The two companies say their distributors and customers differ, so sharing overseas buyer networks could widen sales channels.

The company highlights its CE, KFDA and JFDA certifications and describes itself as the only Korean company supplying AEDs to Japan.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩11.3B₩2.4B21.3%
2025Q4₩15.7B₩4.1B25.8%
2026Q1₩15.3B₩2.5B16.6%
2026Q2₩20.2B₩6B29.6%
2026Q3₩13.6B₩2.2B16.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩47B₩10.8B₩9.1B23.0%15.6%49.5%
2023₩41.8B₩4.9B-₩8.2B11.8%−15.3%58.0%
2024₩40.6B₩7.8B-₩3.2B19.2%−5.5%74.6%
2025₩48.2B₩10.8B₩800M22.4%1.4%67.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue went from KRW 47 billion in 2022 to KRW 41.8 billion in 2023 (down 11.0% year on year) and KRW 40.6 billion in 2024 (down 2.8%), before rising to KRW 48.2 billion in 2025 (up 18.7%), the largest year of 2022 to 2025.

Operating profit fell from KRW 10.8 billion in 2022 to KRW 4.94 billion in 2023 (down 54.2%), the low point, then rose to KRW 7.8 billion in 2024 (up 57.9%) and KRW 10.8 billion in 2025 (up 38.6%). The operating margin was 23.0% in 2022, 11.8% in 2023, 19.2% in 2024 and 22.4% in 2025, close to the 2022 level in 2025.

Net profit attributable to controlling shareholders moved from KRW 9.09 billion in 2022 to a net loss of KRW 8.2 billion in 2023, a continued but smaller loss of KRW 3.2 billion in 2024, and a return to profit of KRW 819 million in 2025.

Net profit including non-controlling interests followed the same direction, at KRW 9.18 billion in 2022, a net loss of KRW 8.14 billion in 2023, a net loss of KRW 3.14 billion in 2024 and KRW 819 million in 2025.

The company attributed the one-time losses to the exit from its hospital management support (MSO) business and to the recovery of invested funds, and said the wind-down was completed by 2025.

The debt ratio rose from 49.5% in 2022 to 74.6% in 2024 before easing to 67.0% in 2025, when total equity was KRW 59.7 billion and total liabilities KRW 40 billion. Operating cash flow was KRW 3.12 billion in 2022, KRW 8.28 billion in 2023, KRW 14.1 billion in 2024 and KRW 9.69 billion in 2025, peaking in 2024.

On a quarterly basis, the company posted an attributable net loss of KRW 2.35 billion in the fourth quarter of 2025 before returning to an attributable profit of KRW 2.99 billion in the first quarter of 2026 and KRW 7.13 billion in the second quarter.

In the third quarter of 2026 revenue was KRW 13.6 billion and operating profit KRW 2.2 billion, with an attributable net loss of KRW 90.43 million, a swing to loss from a year earlier.

In a preliminary tally announced on November 17, 2026, the company put Bistos's contribution to first-to-third-quarter consolidated revenue at KRW 9.8 billion, and it cited export shipment timing and exchange rates as the factors behind the separate-basis decline in the third quarter.

05

Industry analysis

The company attributed the improvement in its 2025 results to rising demand for automated external defibrillator installations in Europe and an expanded local sales network. It said it has been entering new countries and that fast delivery, easy maintenance and product quality have led to larger order intake.

Because exports are a high share of sales, quarterly results can swing with exchange rates and shipment timing, a pattern the company itself cited in the third quarter of 2026.

Money Today reported that listed medical device companies averaged an operating margin of 8.1% in 2024, and said CU Medical Systems' 22.4% margin in 2025 was roughly three times that level.

The industry signals visible in public sources are installation growth overseas, centered on Europe and Japan, and a product replacement phase for newer models. According to the company, AED pads and batteries need periodic replacement, so consumable demand builds as the installed base grows.

The maternal and neonatal subsidiary serves hospital and home-use markets, which broadens a business that was centered on emergency care. The two companies exhibited together at MEDICA 2026 to share overseas sales channels.

The company's competitive strengths rest on its own description of international certifications, its Japan supply history and its overseas distribution network.

06

Outlook

The company has described 2026 as the start of faster growth, pursuing the launch of its next-generation AED CU-SPX and a larger share of the Japanese market. It has said it will keep raising the share of overseas revenue.

It also plans to use the expansion of its global business, including overseas subsidiaries in Germany and Japan, as a medium-term growth base.

Through November 19, 2026, the end of MEDICA 2026, the company is demonstrating new products and meeting global buyers and distribution partners to look for supply expansion opportunities.

In its third-quarter 2026 announcement, a company official said it expects to keep growing in the fourth quarter, citing full-scale overseas supply of CU-SPX and synergy with the subsidiary. The subsidiary is expanding its Yongin plant and expects to be able to meet rising overseas orders.

The company has also said it continues to review measures to enhance shareholder value. However, the direction it has presented centers on new products and overseas expansion, and quarterly results still depend on shipment timing.

The next checkpoint is the annual revenue and operating margin in the 2026 annual report, and before that, any overseas contracts disclosed after MEDICA 2026 would be an early signal of CU-SPX supply expansion.

07

Valuation

PER
2.9×
PBR
0.3×
ROE
11.7%
EPS
₩655
BPS
₩5,793
Dividend per share
₩0

Market capitalization sits below total equity of KRW 59.7 billion at the end of 2025, so the stock trades at a low multiple of book value.

Because net losses attributable to controlling shareholders continued through 2023 and 2024, earnings-based multiple comparisons only became meaningful after the return to profit in 2025.

Attributable net profit of KRW 7.68 billion over the latest four quarters provides a reference point for earnings relative to the share price. The 5-to-1 share consolidation that took effect on April 28, 2026 reduced the share count, so per-share figures are difficult to compare directly with earlier years.

Dividends are at a low level, so shareholder returns have centered on capital-structure steps such as early redemption and cancellation of convertible bonds. In July 2026 the company decided to acquire and cancel KRW 2 billion of convertible bonds before maturity.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Profit recovery on overseas demand

The 2025 operating margin of 22.4% recovered sharply from the 11.8% low in 2023 and came close to the 23.0% of 2022. The company attributed higher sales to rising AED installation demand in Europe and a wider local sales network.

According to the company, about 80% of revenue comes from overseas, so overseas orders are the core of the earnings recovery. Revenue of KRW 20.2 billion and operating profit of KRW 5.97 billion in the second quarter of 2026 were the largest of the last five quarters.

New model and Japan expansion plan

The company has described 2026 as the start of faster growth, pursuing the launch of its next-generation AED CU-SPX, which automatically analyzes rhythm and guides users by voice, and a larger share of the Japanese market. The product is being shown at MEDICA 2026 to overseas buyers and distribution partners.

The company describes itself as the only Korean company supplying AEDs to Japan. According to the company, if the new model leads to overseas supply, consumable sales such as pads and batteries should grow with the installed base.

Consolidation benefits and balance-sheet clean-up

In a preliminary tally announced on November 17, 2026, the company put the subsidiary's contribution to first-to-third-quarter consolidated revenue at KRW 9.8 billion. The company says the wind-down of its non-core hospital management support business was completed in 2025, removing related risk.

The debt ratio fell to 67.0% at the end of 2025 from 74.6% in 2024. In July 2026 the company decided to acquire KRW 2 billion of convertible bonds before maturity and cancel them, one of several steps to reduce potential dilution.

09

Bear factors

Large quarterly swings

Operating profit fell from KRW 5.97 billion in the second quarter of 2026 (up 136.4% from the prior quarter) to KRW 2.2 billion in the third quarter (down 63.1% from the prior quarter) within a single quarter.

In the third quarter, an attributable net loss of KRW 90.43 million marked a swing to loss from a year earlier. The company cited shipment timing and exchange rates as sources of quarterly variation. Even if the annual trend improves, quarterly disclosures could again show losses, which is the core bearish point.

A thin earnings base

Net losses attributable to controlling shareholders continued through 2023 and 2024, and the return to profit came only in 2025. Attributable net profit of KRW 819 million in 2025 is small compared with operating profit of KRW 10.8 billion. Attributable net profit over the latest four quarters totals KRW 7.68 billion.

Because the profitable period is still short, the record that the earnings trend can be sustained is limited, which is a bearish point.

Overseas dependence, currency and dilution

According to the company, about 80% of revenue comes from overseas, so currency movements feed directly into won-denominated results. The company also cited exchange rates as a factor in the third-quarter decline.

It has acquired KRW 2 billion of the KRW 7 billion convertible bonds issued in March 2026 before maturity and plans to pursue early acquisition of the rest. If the remaining bonds convert into shares, the share count would rise, so dilution remains a bearish factor.

10

Risk factors

Currency and overseas concentration

With about 80% of revenue from overseas, a stronger won or shifts in demand in key export markets feed straight into results. As Europe's share of revenue rises and Japan is a stated growth target, procurement policy and regulatory changes in those regions matter more.

The company is widening its distribution network, but its high dependence on specific regions makes the degree of geographic diversification the next item to watch.

Quarterly earnings visibility

The company has explained that quarterly variation arises from shipment timing. The gap between revenue of KRW 20.2 billion in the second quarter of 2026 and KRW 13.6 billion in the third quarter illustrates this.

When export shipments fall on either side of a quarter boundary, sales and profit can swing sharply, which makes the trend hard to read from quarterly figures alone.

Capital structure and dilution

Of the KRW 7 billion convertible bonds issued in March 2026, KRW 2 billion was acquired early and cancelled in July 2026, and the remainder is being pursued for early acquisition before maturity.

The 5-to-1 share consolidation effective on April 28, 2026 reduced the share count, but the possibility of conversion of the remaining bonds remains. Whether the capital base of total equity of KRW 59.7 billion and total liabilities of KRW 40 billion at the end of 2025 holds is the point to verify.

11

What to watch next

  1. November 19, 2026

    The last day of MEDICA 2026. Whether overseas contracts or distribution partners are disclosed from the exhibition would be an early signal of CU-SPX export expansion.

  2. End of March 2027

    The filing date for the 2026 annual report. Annual revenue and operating margin should be compared with KRW 48.2 billion and 22.4% in 2025, and the fourth-quarter 2026 result will show whether it offset the third-quarter loss.

  3. Mid-May 2027

    The filing window for the first-quarter 2027 report. Comparing with first-quarter 2026 revenue of KRW 15.3 billion and operating profit of KRW 2.53 billion will show whether the subsidiary's consolidation effect holds.

  4. Ongoing disclosures from November 2026

    Disclosures on early acquisition and cancellation of the remaining convertible bonds. How far the change in the share count is set is the point to confirm.

12

Overall view

CU Medical Systems showed a recovery in earnings capacity, with a return to profit in 2025 and higher results in the second quarter of 2026. The 22.4% operating margin in 2025 came close to the 23.0% of 2022.

In the third quarter of 2026, however, revenue of KRW 13.6 billion and an attributable net loss of KRW 90.43 million brought quarterly volatility back, and attributable net profit over the latest four quarters totals KRW 7.68 billion.

With about 80% of revenue from overseas, exchange rates and shipment timing drive quarterly results. Expanded overseas supply of the new CU-SPX model and the consolidation of the subsidiary are cited as growth drivers, and their scale will be visible in the 2026 annual report.

The debt ratio fell to 67.0% at the end of 2025 from 74.6% in 2024, while the handling of the remaining convertible bonds stays a variable for the capital structure. This report contains no investment rating or target price.

The next checkpoints are the annual operating margin in the 2026 annual report and the revenue trend in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. calculator.io.kr
  2. cu911.com
  3. news.mt.co.kr
  4. m.sedaily.com
  5. sentv.co.kr
  6. m.irgo.co.kr
  7. jobkorea.co.kr
  8. m.news.nate.com
  9. view.asiae.co.kr
  10. view.asiae.co.kr
  11. newsprime.co.kr
  12. vegannews.co.kr
  13. sentv.co.kr
  14. mt.co.kr
  15. view.asiae.co.kr
  16. m.news.nate.com
  17. view.asiae.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis